恩替卡韦联合扶正化瘀片治疗慢性乙型肝炎后肝硬化的临床效果分析

Entecavir combined with Fuzheng Huayu tablets on chronic hepatitis B infection-induced liver cirrhosis:an analysis of the clinical effects

目的探讨恩替卡韦联合扶正化瘀片治疗慢性乙型肝炎后肝硬化患者的临床效果。方法选取2017年3月至2020年3月我院收治的慢性乙型肝炎后肝硬化患者100例为观察对象,采用随机数字法分为对照组和联合组,每组50例。对照组患者接受常规对症治疗及恩替卡韦分散片治疗,联合组患者在对照组的基础上给予扶正化瘀片辅助治疗,疗程24周。比较两组患者的临床疗效;比较两组患者治疗前后的外周血透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)水平;比较两组患者的乙型肝炎病毒转阴率和药物不良反应发生情况。结果联合组患者的临床疗效明显优于对照组(P<0.05)。治疗24周后,两组患者的HA、LN、PCⅢ、Ⅳ-C水平均显著降低,联合组患者的水平显著低于对照组,差异有统计学意义(P<0.05);两组患者的乙肝病毒表面抗原(HBsAg)、乙肝病毒e抗原(HBeAg)、HBV-DNA转阴率以及不良反应发生率比较,差异均无统计学意义(P>0.05)。结论恩替卡韦联合扶正化瘀片治疗慢性乙型肝炎后肝硬化的临床疗效确切,能有效改善患者的肝纤维化状况,但不增加不良反应。

Objective To explore the clinical effects of entecavir combined with Fuzheng Huayu tablets in the treatment of chronic hepatitis B infection-induced liver cirrhosis.Methods A total of 100 patients with chronic hepatitis B infection-induced liver cirrhosis who were admitted to our hospital from March 2017 to March 2020 were selected as the observation objects.The random number method was used to divide the patients into control group and combined group,with 50 cases in each group.The patients in the control group received conventional symptomatic treatment and entecavir dispersible tablets,based on which the combination group administrated Fuzheng Huayu tablets as adjuvant therapy.The two groups were treated for 24 weeks.The clinical efficacy and the pre-and post-treatment levels of peripheral blood hyaluronidase(HA),laminin(LN),procollagen typeⅢ(PCⅢ)and collagen typeⅣ(Ⅳ-C),as well as the negative rate of hepatitis B virus and the occurrence of adverse drug reactions were compared between the two groups.Results The clinical efficacy of the combined group was significantly superior to that of the control group(P<0.05).After 24 weeks of treatment,the levels of HA,LN,PCⅢ,andⅣ-C significantly decreased in both groups,and the combination group yielded lower levels mentioned above as compared with the control group,with statistically significant differences(P<0.05).There were no statistically significant differences in hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg),HBV-DNA conversion rate and the incidence of adverse reactions between the two groups(P>0.05).Conclusion Entecavir combined with Fuzheng Huayu tablets has a definite clinical effect in the treatment of chronic hepatitis B infection-induced liver cirrhosis.It can effectively improve liver fibrosis condition in patients,whereas it does not increase adverse reactions.